A 4,000% gain is not enough? SanDisk, BioNTech, and Standard Uranium

SanDisk: 4,000% Not Enough?

When it comes to the performance of SanDisk, Micron, and other stocks, we are slowly running out of superlatives. Take SanDisk, for example: 60% in one month, 600% in six months, and 4,000% within a year. The stock is currently trading above USD 1,600, and there is no sign of a major correction.

Analysts are also getting caught up in the euphoria. For example, Barclays recently nearly doubled its price target from USD 1,200 to USD 2,300. While they had previously rated the stock "Equal-Weight," it is now "Overweight." For analysts, SanDisk operates in the most attractive segment of the memory chip sector, just below the "actual" AI chips offered by companies like NVIDIA. Analysts were enthusiastic about the fact that SanDisk currently appears to be successfully securing long-term supply contracts at high prices.

From the company's own perspective as well, the immense rise in the stock price reflects the growing importance of memory components in the global AI race. According to SanDisk CTO Alper Ilkbahar, the market is currently shifting from pure computing power toward a memory-centric architecture. In an interview with "Nikkei Asia," he pointed out that growing language models, complex workloads, and technologies such as key-value caches and mixture-of-experts models require enormous storage capacities. As a result, customers are willing to secure scarce capacities through long-term contracts. To meet the rising demand for AI inference applications, SanDisk is developing the new High Bandwidth Flash format in a standardization partnership with SK Hynix, which offers significantly higher capacity and storage density than conventional High Bandwidth Memory while maintaining similar bandwidth. Initial product samples are planned for the end of the year, with a market launch scheduled for the following year.

Standard Uranium: An Exciting Stock for the Next Uranium Rally

For contrarian investors, an opportunity currently exists in the uranium sector. The industry is also benefiting from the AI boom but is not (yet) driven by the hype. Shares of industry heavyweight Cameco have gained only 9% so far this year.

The trend is similar for Standard Uranium. Yet the stock appears to have significant upside potential. CEO Jon Bey certainly left this impression with his presentation at the IIF digital investor conference. The uranium explorer is excellently positioned in Canada's Athabasca Basin. The flagship Davidson River project spans approximately 31,000 hectares and is surrounded by projects from industry giants such as Cameco, Orano, and NexGen Energy.

According to its own reports, Standard Uranium has identified approximately 71 km of conductive structures, which are considered promising indicators of high-grade uranium discoveries. A new multi-physics approach developed in collaboration with Fleet Space also drew attention. This approach has revealed gravimetric anomalies, enabling more precise drilling targets.

In his presentation, Bey also highlighted the upcoming drilling program. A program initially planned for 5,000 m is set to begin as early as June 2026, with the potential to expand to more than 10,000 m. Bey emphasized that earlier exploration work had already yielded promising indications, but that the crucial gravimetric data had been lacking until now. With the new data, Standard Uranium now considers itself significantly better positioned to potentially make a major basement-hosted uranium discovery in the southwest of the Athabasca Basin. In parallel, the company expects to receive assay results from the Corvo and Rochas/Roché projects in the coming months.

In addition, management highlighted the so-called "Project Generator" model. Under this model, Standard Uranium develops projects to the point of being drill-ready and then brings in partners through earn-in and joint venture models. This is intended to partially cover exploration costs through partner companies without significantly diluting existing shareholders. Bey also commented positively on the return of the high-grade Sun Dog project to the company's own portfolio after a former partner withdrew. Overall, the company considers itself strategically well-positioned amid rising global uranium demand driven by new nuclear power plants, AI data centers, and expected supply shortages.

https://youtu.be/Ip4xhV6gDD8?si=YJMW2ZOPtll2E6eB

BioNTech: Price Target Rises—New Momentum Starting?

While BioNTech currently lacks any momentum, UBS has issued a positive assessment. Analysts have upgraded the stock of Germany's largest biotech group from "Neutral" to "Buy." The price target rises from USD 117 to USD 135. The stock is currently trading at USD 92. Analysts expect upcoming news from the oncology pipeline to be convincing. Therefore, they say, investors' current skepticism is exaggerated.

Perhaps BioNTech's participation in the American Society of Clinical Oncology (ASCO) annual meeting, which begins today, will provide new momentum. Progress from the oncology pipeline is set to be presented there, with a particular focus on data from late-stage clinical development programs. The focus is on the drug candidates Pumitamig and Gotistobart, both of which are being investigated for cancer indications with high unmet medical needs. In the ongoing Phase 2/3 ROSETTA Lung-02 study, Pumitamig demonstrated encouraging anti-tumour activity in non-small cell lung cancer when used in combination with chemotherapy. According to BioNTech, this is already the third global dataset to deliver positive results for the bispecific immunomodulator. The study encompasses different histologies as well as various PD-L1 expression levels and forms the basis for further regulatory Phase 3 development.

BioNTech is also presenting new clinical data for the candidate Gotistobart. In a Phase 2 study in heavily pretreated patients with platinum-resistant ovarian cancer, the combination of Gotistobart and pembrolizumab demonstrated sustained antitumor activity and clinically relevant overall survival rates with a manageable safety profile, according to the company. The results are intended to underscore the potential of the CTLA-4-targeted agent as a chemotherapy-free treatment option. In total, BioNTech is currently advancing more than 25 Phase 2 and 3 clinical trials, including 13 regulatory programs.

SanDisk is currently unstoppable, but anyone buying now must expect a sharp correction. In contrast, the downside potential for Standard Uranium appears to be limited. It can really only be a matter of time before investors rediscover uranium stocks as AI winners. The company should provide significant news flow in the coming weeks. With BioNTech, much of the negative news seems to be priced in. However, a "Buy" is not yet a foregone conclusion.